Immunocore company information, Employees & Contact Information

Immunocore reports second quarter financial results and provides a business update Yahoo Finance

Immunocore Holdings plc to Report Q2 2025 Financial Results and Host Investor Call on August 7, 2025 Quiver Quantitative

A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1c+ cells Frontiers

Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies ScienceDirect.com

Immunocore Outlines Strategic Priorities for 2025 to Expand Access to KIMMTRAK and Advance Clinical Trials Nasdaq

Immunocore to Present at the 2025 Jefferies Global Healthcare Conference 富途牛牛

Immunocore to present at upcoming investor conferences | User | woonsocketcall.com FinancialContent

NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma OncLive

Immunocore Doses First Patient in Phase 1 Trial of IMC-P115C, a Half-Life Extended ImmTAC Candidate for Advanced Solid Tumors Quiver Quantitative

GingisREX: A Complementary Enzyme for the Detection of Bacterial Proteins ACS Publications

Immunocore Secures $130 Million Series B Financing General Atlantic

Immunocore Boosts its Collaboration with GSK with new Lead Compound Labiotech.eu

An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis PNAS

A career at the frontier of immunotherapy New Scientist

Stocks Showing Improved Relative Strength: Immunocore Holdings ADR Investor's Business Daily

Immunocore Announces Upcoming Presentations at the American GlobeNewswire

Immunocore Secures NHS Reimbursement for KIMMTRAK in England for Uveal Melanoma Treatment Quiver Quantitative

Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... Yahoo Finance

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy Yahoo Finance

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet Yahoo Finance

Immunocore’s tebentafusp granted Breakthrough Therapy GlobeNewswire

Structure-guided stabilization of pathogen-derived peptide-HLA-E complexes using non-natural amino acids conserves native TCR recognition Wiley Online Library

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO PharmaVoice

Cell-targeted PD-1 agonists are potent NK-cell inhibitors Frontiers

Immunocore: A Commercial Biotech Nearing Its Pivotal Break Even-Point (NASDAQ:IMCR) Seeking Alpha

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? Yahoo Finance

#ASCO24: Immunocore unveils early-stage data of skin cancer treatment that led it to start Phase 3 trial Endpoints News

Immunocore Approvals Open Door for TCR Cancer Drugs Labiotech.eu

How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science PharmaVoice

Er-Kim Announces Exclusive Agreement with Immunocore to GlobeNewswire

Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients Fierce Biotech

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand PR Newswire

Immunocore initiated at neutral at Guggenheim as Kimmtrak priced into shares Seeking Alpha

Immunocore Announces Proposed Convertible Senior Notes Offering Stock Titan

Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry? simplywall.st

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells Wiley Online Library

Immunocore claims first-ever FDA approval for TCR cancer therapy pharmaphorum

New melanoma drug a step closer to the clinic cancer.ox.ac.uk

TCR‐induced alteration of primary MHC peptide anchor residue - Madura - 2019 - European Journal of Immunology Wiley Online Library

Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode Insider Monkey

Immunocore Q2 2025 Financial Results and Business Update TradingView

Immunocore gets FDA breakthrough nod for eye melanoma drug ahead of planned Q3 filing Fierce Biotech

Immunocore (IMCR) Zacks Investment Research

Immunocore IPO filing reveals kickback scheme, Immatics row and phishing attacks Fierce Biotech

Another AstraZeneca executive hits the exit, joins alumnus at Immunocore Fierce Biotech

GlaxoSmithKline culls early-stage Immunocore med as well as DMD asset in Q1 clear-out Fierce Biotech

Roche builds on Immunocore ImmTAC deal PMLiVE

Former Immunocore and GSK researcher named Zelluna CSO The Pharma Letter

FierceBiotech's 2013 Fierce 15 Fierce Biotech

GSK signs $500m-plus technology deal with Immunocore PMLiVE